Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05817890 · ClinicalTrials.gov registry record · Early Phase 1
Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects
A Early Phase 1 study, sponsored by Cyclacel Pharmaceuticals.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT05817890: Completed Early Phase 1 study, sponsored by Cyclacel Pharmaceuticals.
NCT05817890 is a Early Phase 1 study that has completed, run by Cyclacel Pharmaceuticals. The registered enrollment target is 8 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05817890, a Early Phase 1 study, has completed, sponsored by Cyclacel Pharmaceuticals.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This will be a Phase 1, open-label, single dose study of the Absorption, Metabolism, and Excretion of CYC065 in healthy male subjects.
Primary Outcome
Total radioactivity from \[14C\]-CYC065 recovery (fet1t2) in urine and feces
Interventions
- DRUG Fadraciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-03-03 |
| Est. Completion | 2024-05-22 |
| Phase | Early Phase 1 |
What the finished NCT05817890 record still lists
NCT05817890 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which Fadraciclib is the first listed.
NCT05817890 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05817890 about?
NCT05817890 is a clinical study titled "Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects". This will be a Phase 1, open-label, single dose study of the Absorption, Metabolism, and Excretion of CYC065 in healthy male subjects.
What is the current status of trial NCT05817890?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2023-03-03. Estimated completion is 2024-05-22.
What interventions are being tested in trial NCT05817890?
The interventions under investigation include: Fadraciclib (DRUG).
Who is sponsoring clinical trial NCT05817890?
This trial is sponsored by Cyclacel Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05817890's enrollment target sits among peer trials
8 1782nd of 2000 higher than 176 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI